The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2019

Genetically Modified Organisms (Contained Use) Regulations 2014 U.K.

40.—(1) The Genetically Modified Organisms (Contained Use) Regulations 2014 M1 are amended as follows.

(2) In regulation 3(2)—

(a) in sub-paragraph (a) omit paragraph (iii);

(b) in sub-paragraph (b), for paragraph (i) substitute—

“(i) a medicinal product for veterinary use marketed in accordance with the Veterinary Medicines Regulations 2013 M2 ;”.

(3) After regulation 33 insert—

“Transitional provision in relation to the withdrawal of the United Kingdom from the European Union

33A.— (1) Subject to paragraphs (2) and (3), these Regulations do not apply to any activity which is covered by a written consent given by a competent authority of an EEA State in accordance with Article 15(3), 17(6) or 18(2) of Directive (EC) No 2001/18 of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms M3 .

(2) The written consent referred to in paragraph (1) must be valid immediately before [F1 IP completion day].

(3) Any activity covered by the consent referred to in paragraph (1) must be conducted in accordance with any obligations, conditions or limitations attached to that consent.

(4) Subject to paragraphs (5) and (6), these Regulations do not apply to any genetically modified organisms which are cultured, stored, transported, destroyed, disposed of or used, where such organisms are, or are contained in, a medicinal product for human or veterinary use marketed in accordance with an authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

(5) The marketing authorisation referred to in paragraph (4) must be valid immediately before [F1 IP completion day].

(6) Any marketing authorisation referred to in paragraph (4) must be conducted in accordance with any obligations, conditions, restrictions, requirements or limitations attached to that authorisation.”

(4) In Schedule 3, in paragraph 3 for sub-paragraph (d) substitute—

“(d) consideration of relevant legislation, including legislation on the protection of workers from risks related to exposure to biological agents at work, other classification schemes referring to plant and animal pathogens, and other international and national classification schemes for genetically modified micro-organisms;”.

Textual Amendments

F1 Words in Sch. 1 para. 40(3) substituted (31.12.2020 immediately before IP completion day) by The Chemicals (Health and Safety) and Genetically Modified Organisms (Contained Use) (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1567), reg. 1(2), Sch. 1 para. 19

Commencement Information

I1 Sch. 1 para. 40 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(2)

Marginal Citations

M1 S.I. 2014/1663, amended by S.I. 2015/1637.

M2 S.I. 2013/2033, amended by S.I. 2014/599, 2018/761.

M3 OJ No. L 106, 17.04.2001, p.1.